Lungpacer Medical USA, Inc.

Lungpacer Medical is a Vancouver-based medical device manufacturer specializing in minimally invasive respiratory and critical care solutions. The company's flagship AeroPace® Neurostimulation System is a temporary transvenous diaphragm strengthening therapy that stimulates phrenic nerves to restore independent breathing and accelerate mechanical ventilation weaning in critically ill ICU patients. The catheter-based system integrates seamlessly into existing critical care workflows without requiring surgical intervention. Clinical evidence demonstrates the AeroPace System achieves 43% faster weaning from mechanical ventilation over 30 days, reduces ICU days on mechanical ventilation by 3.2 days, and reduces reintubation risk by 47% and tracheostomy risk by 50% compared to standard-of-care. Founded in 2009, Lungpacer received FDA emergency use authorization in 2020 and full FDA premarket approval in December 2024. The company has secured CMS reimbursement approval and is conducting advanced trials including the STARI study investigating next-generation continual neurostimulation therapy.